Global Liquid Biopsy Market
Liquid Biopsy Market Size And Forecast
According to Verified Market Research, The Global Liquid Biopsy Market was valued at USD 1063.71 million in 2019 and is projected to reach USD 5027.46 million by 2027, growing at a CAGR of 23.12% from 2020 to 2027.
Global Liquid Biopsy Market Overview
With the advent of technological advancement in the healthcare sector, areas of medicine such as the diagnosis and treatment through progressive technology and minimally invasive procedures have therefore grown significantly as a result. With non-invasive or minimally invasive methods in general, there are several advantages as compared to its counterpart as it involves the drastic increase in overall patient safety as well as leads to enhanced customer satisfaction through decreasing or eliminating the overall patient recovery time.
On the other hand, the lack of skilled professionals and a lack of knowledge about liquid biopsy will pose a challenge to the growth of the market at a global level.
Liquid Biopsy Market Competetive Landscape:
Liquid Biopsy Market is highly fragmented with the presence of a large number of players globally. Some of the major companies include Biocept, Inc., Qiagen, F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Myriad Genetics, Janssen Diagnostics, LLC, Trovagene Inc., Guardant Health Inc., GRAIL, and MDX Health SA.
Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.